Global Genitourinary Drugs Market are anticipated to grow at a low CAGR during the forecast period. The genitourinary drugs market is anticipated to witness a considerable growth rate due to the rising prevalence of genitourinary diseases and growing awareness regarding it. As per the Centers for Diseases Control and Prevention (CDC), urinary tract infections are a common infection demanding medical care and causing around 9.6 million ambulatory care visits. The economic burden of urinary tract infection is around $ 2 million per year. However, the growing advent of counterfeit drugs and lack of compliance to medication are the factors that are hampering the growth of the genitourinary drugs market.The factor such as growing healthcare expenditure, increasing per capita income and rising aging population has witnessed a positive impact on the growth of the genitourinary drugs market in emerging economies. The improvement of the healthcare infrastructure that includes a robust increase in the number of clinics and hospitals is expected to boost the growth of the market.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/genitourinary-drugs-market
The genitourinary disorders are the conditions in the urinary tract and genital organs. The condition in these parts of the human body may occur owing to several bacterial infections. These drugs are used for the treatment of various diseases includes erectile dysfunction, urinary tract infections, urinary incontinence, glomerulonephritis, chronic renal failure, and genitourinary cancers. Lifestyle disorders that include strokes and autoimmune conditions such as obesity, multiple sclerosis, and diabetes or age-related ailments including Alzheimer’s are considered responsible for genitourinary conditions. The prevalence of health conditions is growing across the globe owing to a sedentary lifestyle. Such a large prevalence of genitourinary disorders propels the growth of the market over the forecast period.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/genitourinary-drugs-market
Market Segmentation
Global Genitourinary Drugs Market by Product
- Hormonal Therapy
- Impotence Agents
- Uterine Relaxants
- Urinary Antispasmodics
- Urinary pH Modifiers
- Uterine Stimulants
- Miscellaneous Genitourinary Tract Agents
Global Genitourinary Drugs Market by Disease
- Erectile Dysfunction
- Urinary Tract Infections
- Urinary Incontinence
- Glomerulonephritis
- Chronic Renal Failure
- Genitourinary Cancers
- Other Diseases(STD)
Regional Analysis
North America
- US
- Canada
Europe
- UK
- Germany
- Italy
- Spain
- France
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- Rest of Asia-Pacific
Rest of the World
Company Profiles
- Abbott Laboratories
- Allergan PLC
- AstellasPharma US, Inc.
- AstraZeneca PLC
- Bayer AG
- Bristol-Myers Squibb Co.
- Cipla USA, Inc.
- Eli Lilly & Co.
- Genentech, Inc.
- GlaxoSmithKline PLC
- Hoffman-La Roche AG
- Ionis Pharmaceuticals, Inc.
- Johnson & JohnsonService, Inc.
- Melinta Therapeutics, Inc.
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Sanofi S.A.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
